Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Dapagliflozin 10 mg tablets vs Forxiga 10 mg tablets in healthy Thai volunteers under fasting conditions
TCTR20260324004Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin (2 arms), sponsored by Bio-innova. Primary endpoint: Primary bioequivalence pharmacokinetic parameters. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
Beyond the preview
Go deeper on TCTR20260324004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260324004.